Cheng E Chee, Melissa Ooi, Soo-Chin Lee, Raghav Sundar, Valerie Heong, Wei-Peng Yong, Chin Hin Ng, Andrea Wong, Joline S J Lim, David S P Tan, Ross Soo, Joshua T C Tan, Song Yang, Min Thura, Abdul Qader Al-Aidaroos, Wee Joo Chng, Qi Zeng, Boon-Cher Goh
BACKGROUND: Phosphatase of regenerating liver-3 (PRL-3) is involved in cellular processes driving metastasis, cell proliferation, invasion, motility and survival. It has been shown to be upregulated and overexpressed in cancer tissue, in contrast to low or no expression in most normal tissue. PRL3-zumab is a first-in-class humanized antibody that specifically binds to PRL-3 oncotarget with high affinity and has been shown to reduce tumor growth and increase survival. OBJECTIVE: In the study, we aimed to determine the safety and efficacy of PRL3-zumab in patients with advanced solid tumors and hematological malignancies...
April 15, 2023: Targeted Oncology